Skip to main content

Advertisement

Table 1 Countries with high endemic rates (>10 cases/100,000 population) and/or > =1 epidemic over the last 20 years

From: Global epidemiology of invasive meningococcal disease

Country Year Incidence/100,000 population Predominant serogroup Source Comments
African Region
Angola 1994–2000 19–230 * [8]  
Benin 1980–1999 6–57   [9, 10]  
Burkina Faso 2004–2009 26–187   [11, 12]  
Burundi 1980–1999 158   [9]  
Cameroon 1–224   [13]  
Centrafique 2004–2009 3 3–19.4   [12]  
Chad 9.6–15.9   [12]  
Cote de Ivoire 1980–1999 0-6   [14] Despite its relatively low attack rate, Cote de Ivoire is included in this table due to its location in the meningitis belt
Ethiopia 0–104 A [9, 10]  
Gambia 4–165   [9, 15]  
Ghana 0–108   [9, 15]  
Guinea 0–17   [12]  
Guinea Bissau 0–133   [9]  
Kenya 1990 267   [16]  
Mali 2004–2009 2.6–12.9   [12]  
Mauritania 1980–1999 0–14   [9]  
Namibia 4–165   [9]  
Niger 2004–2009 7.8–90.7   [17]  
Nigeria 0.7–52.6   [12]  
RD Congo 7.3–23.7   [12]  
Rwanda 1980–1999 0–28   [9]  
Senegal 0–53    Incidence >50 in 1983
Tanzania 1980–1999 0–19    
Togo 2004–2009 6–13.2   [12]  
Uganda 1980–1999 0–18   [14]  
Eastern Mediterranean Region
Sudan 2008 * A [12] Despite lack of data Sudan is included in this table due to its location in the meningitis belt
Saudi Arabia 2000   A, W-135 [18] 225 cases in month after 2000 Hajj season. Data from Saudi Arabia mostly includes cases from the Hajj season.
European Region
No country in this region is in the high rate category
Region of the Americas
Uruguay 2001 30 (pre-vaccine) B [19] Vaccine comprising serogroup C capsular polysaccharide and the outer membrane vesicles of serogroup B meningococcus was used
1.6 (post-vaccine)
South-East Asia Region
No country in this region is in the high rate category
Western Pacific Region
New Zealand 1991–2000 17.4 (pre-vaccine) B [20] An OMV vaccine for Serogroup B was introduced in 2004
2.6 (post-vaccine)
Mongolia 1994–1995 80-90 A [21]  
  1. * Data not available.